Search - Easy Blog
Presentations
Friday, 20 November 2015 00:00

Cancer-associated thrombosis (CAT) in patients with renal dysfunction

The views expressed in this program are the personal views of the experts and do not necessarily reflect the opinion and position of UKidney and the sponsor. The opinions expressed as part of this program might contain information about drugs or indications that have not been approved in Canada. This program was made possible with the support of LEO Pharma Inc. Canada

Program

blood clot playCancer and renal dysfunction both increase the risk of venous thromboembolism (VTE). Anticoagulants are not all the same, and extra consideration is needed in patients with renal dysfunction. Low molecular weight heparin (LMWH) is named as the treatment of choice for cancer-associated thrombosis (CAT) in both Canadian and international guidelines, with a treatment duration of 6 months recommended. Even among the LMWH, there are differences that must be considered for the patient with renal dysfunction.

The speakers will present a case of CAT in a patient with moderate-severe renal dysfunction, as well as information about the differences among anticoagulants and within the LMWH class, use of anticoagulants in patients with renal dysfunction, and the Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer.

Viewed 9534 times Last modified on Monday, 03 October 2016 07:49

Leave your comments

Post comment as a guest

0
Your comments are subject to administrator's moderation.
  • No comments found